[{"id":"e91b36ee-909a-4d08-a98e-cb3dada191eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06756932","created_at":"2025-02-25T14:12:02.732Z","updated_at":"2025-02-25T14:12:02.732Z","phase":"Phase 1","brief_title":"BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer","source_id_and_acronym":"NCT06756932","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • BGB-21447"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 02/04/2025","start_date":" 02/04/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-17"},{"id":"65986e74-a9bc-495d-9648-8e352d126636","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828589","created_at":"2023-04-25T14:03:41.618Z","updated_at":"2024-07-02T16:35:14.643Z","phase":"Phase 1","brief_title":"A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies","source_id_and_acronym":"NCT05828589","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":" | ","alterations":" MYC translocation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BGB-21447"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-03-15"}]